Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy
NCT ID: NCT01219452
Last Updated: 2010-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
30 participants
INTERVENTIONAL
2010-10-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
umbilical cord mesenchymal stem cells
intramuscular injection of umbilical cord mesenchymal stem cell
umbilical cord mesenchymal stem cells
Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
umbilical cord mesenchymal stem cells
Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* They should have symptoms and /or signs of heart failure, despite optimized medical treatment.
* Ejection fraction of left ventricular should be less than 50%, but more than 20%.
Exclusion Criteria
* any history or suspicion of a toxic , pharmacologic or deposit etiology.
* associated malignant or pre -malignant systemic disease.
* associated hematologic disorder.
* a history of sustained ventricular tachycardia or fibrillation.
* a history of syncope during the previous year, or with an active infectious disease or positive tests to viral disease.
1 Year
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qingdao University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Organization: Stem Cell Research Center of Medical School Hospital of Qingdao University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
zipu li, MD Phd
Role: STUDY_DIRECTOR
The Affiliated Hospital of Qingdao University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stem Cell Research Center of Medical School Hospital of Qingdao University
Qingdao, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jianxia Hu, MD
Role: primary
Hong Gao, MS
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MSCKX002
Identifier Type: -
Identifier Source: org_study_id